Sorafenib Encapsulated Poly(ester amide) Nanoparticles for Efficient and Biosafe Prostate Cancer Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Prostate cancer (PCa) is a prevalent global health concern with poor long-term patient prognosis.
• Current treatments face challenges like drug resistance, limited solubility, and rapid metabolism, necessitating novel therapeutic strategies.

Purpose of the Study:

• To develop a nanoparticle-based drug delivery system for sorafenib (SOR) to overcome its limitations in prostate cancer treatment.
• To enhance the solubility, stability, targeting, and bioavailability of SOR for improved therapeutic outcomes.

Main Methods:

• Preparation of sorafenib-loaded nanoparticles (SOR@8P4 NPs) using a phenylalanine-based poly(ester amide) polymer (8P4).
• Evaluation of nanoparticle stability and acid-responsive drug release characteristics.
• In vitro assessment of anticancer, antimetastatic, and antiproliferative effects.
• In vivo studies to determine tumor targeting and tumor growth inhibition.

Main Results:

• SOR@8P4 NPs exhibited high stability and demonstrated acid-responsive drug release in simulated tumor microenvironments.
• In vitro studies showed superior anticancer, antimetastatic, and antiproliferative activities of SOR@8P4 NPs compared to free SOR.
• In vivo experiments confirmed efficient tumor targeting and significant inhibition of tumor growth by SOR@8P4 NPs.

Conclusions:

• The developed SOR@8P4 NPs represent a promising drug delivery system for enhancing sorafenib efficacy in prostate cancer.
• This nanoparticle formulation offers a novel strategy for improving the clinical treatment of prostate cancer by addressing drug limitations.